-transparent.png){kind=logo}
Crilvastatin is a drug from the pyrrolidone family that had been shown to induce non-competitive inhibition of rat hydroxymethylglutaryl-coenzyme A reductase activity in vitro. The aim of this study was to evaluate the activity of crilvastatin on the hepatic metabolism of cholesterol in rats. Crilvastatin increased low density lipoprotein (LDL)-cholesterol uptake by the liver more than high density lipoprotein (HDL) uptake, thus increasing by up 30% the clearance of excess plasma cholesterol. In normolipidemic rats, crilvastatin significantly enhanced acyl coenzyme A:cholesterol acyl transferase and cholesterol 7 alpha-hydroxylase activity. In rats with a previous high cholesterolemia, crilvastatin also enhanced cholesterol 7 alpha-hydroxylase activity and did not increase liver acyl coenzyme A:cholesterol acyl transferase activity. These findings suggest that a drug such as crilvastatin could have a hypocholesterolemic effect by a mechanism other than the sole inhibition of cholesterol synthesis, possibly by stimulating cholesterol and bile salt secretion via the biliary tract in previously hypercholesterolemic rats.
T Clerc, and
M Jomier, and
M Chautan, and
H Portugal, and
M Senft, and
A M Pauli, and
C Laruelle, and
O Morel, and
H Lafont, and
F Chanussot
November 1998,
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
T Clerc, and
M Jomier, and
M Chautan, and
H Portugal, and
M Senft, and
A M Pauli, and
C Laruelle, and
O Morel, and
H Lafont, and
F Chanussot
March 1994,
Der Internist,
T Clerc, and
M Jomier, and
M Chautan, and
H Portugal, and
M Senft, and
A M Pauli, and
C Laruelle, and
O Morel, and
H Lafont, and
F Chanussot
January 1994,
Pharmaceutical research,
T Clerc, and
M Jomier, and
M Chautan, and
H Portugal, and
M Senft, and
A M Pauli, and
C Laruelle, and
O Morel, and
H Lafont, and
F Chanussot
October 1983,
Archives of biochemistry and biophysics,
T Clerc, and
M Jomier, and
M Chautan, and
H Portugal, and
M Senft, and
A M Pauli, and
C Laruelle, and
O Morel, and
H Lafont, and
F Chanussot
January 1996,
Toxicologic pathology,
T Clerc, and
M Jomier, and
M Chautan, and
H Portugal, and
M Senft, and
A M Pauli, and
C Laruelle, and
O Morel, and
H Lafont, and
F Chanussot
January 1981,
Biochimica et biophysica acta,
T Clerc, and
M Jomier, and
M Chautan, and
H Portugal, and
M Senft, and
A M Pauli, and
C Laruelle, and
O Morel, and
H Lafont, and
F Chanussot
February 1971,
FEBS letters,
T Clerc, and
M Jomier, and
M Chautan, and
H Portugal, and
M Senft, and
A M Pauli, and
C Laruelle, and
O Morel, and
H Lafont, and
F Chanussot
August 1995,
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
T Clerc, and
M Jomier, and
M Chautan, and
H Portugal, and
M Senft, and
A M Pauli, and
C Laruelle, and
O Morel, and
H Lafont, and
F Chanussot
January 1992,
Toxicologic pathology,
T Clerc, and
M Jomier, and
M Chautan, and
H Portugal, and
M Senft, and
A M Pauli, and
C Laruelle, and
O Morel, and
H Lafont, and
F Chanussot
February 2002,
The Annals of pharmacotherapy,
